Cargando…

Phase II clinical trial testing the safety of a humanised monoclonal antibody anti-CD20 in patients with heart failure with reduced ejection fraction, ICFEr-RITU2: study protocol

INTRODUCTION: Chronic heart failure with reduced ejection fraction (HFrEF) treatment targets neurohormonal inhibition; however, our experimental observations and the recent clinical evidence in myocardial infarction and heart transplant patients support the anti-inflammatory pathway as a potential n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sánchez-Trujillo, Luis, Jerjes-Sanchez, Carlos, Rodriguez, David, Panneflek, Jathniel, Ortiz-Ledesma, Claudia, Garcia-Rivas, Gerardo, Torre-Amione, Guillermo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475246/ https://www.ncbi.nlm.nih.gov/pubmed/30918029 http://dx.doi.org/10.1136/bmjopen-2018-022826

Ejemplares similares

B-type natriuretic peptide reference interval of newborns from healthy and pre-eclamptic women: a prospective, multicentre, cross-sectional study
por: Rodriguez, David, et al.
Publicado: (2018)

Heart Failure With Midrange Ejection Fraction: Prior Left Ventricular Ejection Fraction and Prognosis
por: Zhang, Xinxin, et al.
Publicado: (2021)

Diabetes Associated With Greater Ejection Fraction Improvement After Revascularization in Patients With Reduced Ejection Fraction
por: Wang, Shaoping, et al.
Publicado: (2021)

Characterisation of a humanised bispecific monoclonal antibody for cancer therapy.
por: Bruynck, A., et al.
Publicado: (1993)

Long term development of diastolic dysfunction and heart failure with preserved left ventricular ejection fraction in heart transplant recipients
por: Vejpongsa, Pimprapa, et al.
Publicado: (2022)

Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain)
por: Farré, Nuria, et al.
Publicado: (2017)

Microvascular Rarefaction and Heart Failure With Preserved Ejection Fraction
por: Zeng, Heng, et al.
Publicado: (2019)

Editorial: Edema in heart failure with reduced ejection fraction
por: Gladysheva, Inna P., et al.
Publicado: (2023)

In vitro and in vivo anticancer efficacy of unconjugated humanised anti-CEA monoclonal antibodies
por: Blumenthal, R D, et al.
Publicado: (2008)

Interatrial Shunt Device for Heart Failure With Preserved Ejection Fraction
por: Kaye, David M., et al.
Publicado: (2019)

Outcomes of Spironolactone Withdrawal in Dilated Cardiomyopathy With Improved Ejection Fraction
por: Chen, Yanjia, et al.
Publicado: (2021)

Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction
por: Graziani, Francesca, et al.
Publicado: (2021)

Resveratrol Prevents Right Ventricle Remodeling and Dysfunction in Monocrotaline-Induced Pulmonary Arterial Hypertension with a Limited Improvement in the Lung Vasculature
por: Vázquez-Garza, Eduardo, et al.
Publicado: (2020)

Reply: In vitro and in vivo anticancer efficacy of unconjugated humanised anti-CEA monoclonal antibodies
por: Ashraf, S Q, et al.
Publicado: (2008)

Humanised monoclonal antibodies neutralise pertussis toxin by receptor blockade and reduced retrograde trafficking
por: Acquaye‐Seedah, Edith, et al.
Publicado: (2018)

Weight Change and Mortality Risk in Heart Failure With Preserved Ejection Fraction
por: Huang, Peisen, et al.
Publicado: (2021)

Association Between Arterial Stiffness and Heart Failure With Preserved Ejection Fraction
por: Chi, Chen, et al.
Publicado: (2021)

Pulmonary Hypertension in Patients With Heart Failure With Mid-Range Ejection Fraction
por: Maeder, Micha T., et al.
Publicado: (2021)

Overcoming the Limits of Ejection Fraction and Ventricular-Arterial Coupling in Heart Failure
por: Antohi, Elena-Laura, et al.
Publicado: (2022)

Diving Into the Diagnostic Score Algorithms of Heart Failure With Preserved Ejection Fraction
por: Abramov, Dmitry, et al.
Publicado: (2021)

Heart failure with preserved ejection fraction—Out with the old and out with the new?
por: Tolento Cortes, Luis, et al.
Publicado: (2022)

Biomarkers of Volume Overload and Edema in Heart Failure With Reduced Ejection Fraction
por: Chiorescu, Roxana Mihaela, et al.
Publicado: (2022)

Skeletal muscle phenotypic switching in heart failure with preserved ejection fraction
por: Saw, Eng Leng, et al.
Publicado: (2022)

Sympathetic and hemodynamic responses to exercise in heart failure with preserved ejection fraction
por: Manabe, Kazumasa, et al.
Publicado: (2023)

Inflammation as a therapeutic target in heart failure with preserved ejection fraction
por: Peh, Zhen Hui, et al.
Publicado: (2023)

Distinct features of calcium handling and β‐adrenergic sensitivity in heart failure with preserved versus reduced ejection fraction
por: Kilfoil, Peter J., et al.
Publicado: (2020)

Smaller left ventricular end-systolic diameter and lower ejection fraction at baseline associated with greater ejection fraction improvement after revascularization among patients with left ventricular dysfunction
por: Wang, Shaoping, et al.
Publicado: (2022)

Role of sex on the efficacy of pharmacological and non-pharmacological treatment of heart failure with reduced ejection fraction: A systematic review
por: Sanromán Guerrero, María Ascensión, et al.
Publicado: (2022)

Large Animal Models of Heart Failure With Reduced Ejection Fraction (HFrEF)
por: Spannbauer, Andreas, et al.
Publicado: (2019)

The Potential Therapeutic Role of Celastrol in Patients With Heart Failure With Preserved Ejection Fraction
por: Ajmal, Maryam, et al.
Publicado: (2021)

Gut Microbiota in Heart Failure Patients With Preserved Ejection Fraction (GUMPTION Study)
por: Huang, Ziyin, et al.
Publicado: (2022)

Predictors and Mortality for Worsening Left Ventricular Ejection Fraction in Patients With HFpEF
por: Chen, Liling, et al.
Publicado: (2022)

Association of Body-Weight Fluctuation With Outcomes in Heart Failure With Preserved Ejection Fraction
por: Li, Yi, et al.
Publicado: (2021)

Body Mass Index: An Effective Predictor of Ejection Fraction Improvement in Heart Failure
por: Ye, Li-fang, et al.
Publicado: (2021)

Advances in Multimodality Cardiovascular Imaging in the Diagnosis of Heart Failure With Preserved Ejection Fraction
por: Del Torto, Alberico, et al.
Publicado: (2022)

Proteomic and phosphoproteomic profiling in heart failure with preserved ejection fraction (HFpEF)
por: Valero-Muñoz, María, et al.
Publicado: (2022)

C-reactive protein and statins in heart failure with reduced and preserved ejection fraction
por: Park, Jin Joo, et al.
Publicado: (2022)

Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China
por: Sang, Haiqiang, et al.
Publicado: (2022)

Machine learning models in heart failure with mildly reduced ejection fraction patients
por: Zhao, Hengli, et al.
Publicado: (2022)

Prognostic implications of left ventricular ejection fraction trajectory changes in heart failure
por: Ding, Zijie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k2elas0u6qlbel5nhn1k568sbj